You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Positive results for Cerevance’s Parkinson’s drug

Cerevance has announced positive phase 2 trial results for the company’s first-in-class, once-a-day, orally-adminstered compound treating Parkinson’s disease.